ARS Pharmaceuticals Inc. (SPRY)
NASDAQ: SPRYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SPRY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $297.56M
- EPS (TTM)
- -$2.01
- Dividend yield
- None
- 52-week range
- 2.44 – 13.15
- Day range
- 2.86 – 3.47
- Volume / Avg
- 2.78M / 1.83M
- Beta
- —
- Shares outstanding
- 100.53M
52-week range
SPRY stock today
Shares of ARS Pharmaceuticals (SPRY) finished lower on Nov 20 at $2.96, a drop of 11.90% or $0.40 per share, versus the S&P 500's 3.70% decline. At this level, SPRY sits near the bottom of its 52-week range of $2.44 to $13.15: 77.5% below the high, set on Jan 12, 2026 and 21.3% above the low. SPRY is down 74.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 61.0%.
ARS Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.01), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ARS Pharmaceuticals
Company profileARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Donn Casale
- Headquarters
- San Diego, CA
- Employees
- 203
- IPO year
- 2020
- Website
- ars-pharma.com
Financial highlights
Full financialsIn fiscal 2025, ARS Pharmaceuticals generated $84.3 million in revenue, down 5.5% from fiscal 2024, its first annual decline since 2023. ARS Pharmaceuticals reported a net loss of $171.3 million, compared with net income of $8.0 million a year earlier. Operating margin was -212.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $84.28M | $89.15M | $30.00K | $1.32M | $5.51M |
| Growth | -5.46% | +297063.33% | -97.72% | -76.10% | — |
| Net income | $-171.30M | $8.00M | $-54.37M | $-34.68M | $-20.24M |
| EPS (diluted) | $-1.74 | $0.08 | $-0.57 | $-0.87 | $-0.70 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$17.00+474.32%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.36 vs $-0.34
- Surprise
- -5.88%
SPRY news
All SPRY newsARS Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EVMNEvommune Inc. | 7.04 | -2.76% | $291.10M | vs SPRY |
| BNTCBenitec Biopharma Inc. | 7.92 | -2.76% | $285.88M | vs SPRY |
| GLSIGreenwich LifeSciences Inc. | 19.25 | -2.73% | $282.56M | vs SPRY |
| FULCFulcrum Therapeutics Inc. | 3.69 | -0.54% | $281.85M | vs SPRY |
| RLMDRelmada Therapeutics Inc. | 2.62 | -15.76% | $279.54M | vs SPRY |
| AVIRAtea Pharmaceuticals Inc. | 3.96 | +0.76% | $318.00M | vs SPRY |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs SPRY |
| LRMRLarimar Therapeutics Inc. | 3.14 | -2.48% | $328.55M | vs SPRY |
Indexes, lists and sector
ARS Pharmaceuticals stock FAQ
What is ARS Pharmaceuticals's stock price today?
SPRY last traded at $2.96 as of Nov 20, 4:00 PM EST, down 11.90% on the day. Prices are delayed at least 15 minutes.
Who is ARS Pharmaceuticals's CEO?
Mr. Donn Casale is the chief executive officer of ARS Pharmaceuticals Inc., which has about 203 employees.
What is the SPRY 52-week high?
The 52-week high for SPRY is $13.15 and the 52-week low is $2.44. The stock is currently 77.5% below its high.